Results 141 to 150 of about 1,227,115 (260)

A proposal for the assessment of replication of effects in single-case experimental designs. [PDF]

J Appl Behav Anal, 2022
Manolov R, Tanious R, Fernández-Castilla B.   +2 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Multi-Objective Optimal Experimental Designs for ER-fMRI Using MATLAB

Journal of Statistical Software, 2009
Designs for event-related functional magnetic resonance imaging (ER-fMRI) that helpto eciently achieve the statistical goals while taking into account the psychological con-straints and customized requirements are in great demand.
Ming-Hung Kao
doaj  

An in-silico analysis of experimental designs to study ventricular function: A focus on the right ventricle. [PDF]

PLoS Comput Biol, 2022
Colebank MJ, Chesler NC.
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Experimental Designs for Preclinical Neuroscience Experiments: Part I-Design Basics. [PDF]

eNeuro
Reynolds PS.
europepmc   +1 more source

Hybrid Experimental Designs for Intervention Development: What, Why, and How. [PDF]

Adv Methods Pract Psychol Sci, 2022
Nahum-Shani I, Dziak JJ, Walton MA, Dempsey W.   +3 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Experimental Designs for Preclinical Neuroscience Experiments: Part 2-Blocking and Blocked Designs. [PDF]

eNeuro
Reynolds PS.
europepmc   +1 more source

Evaluation of the Effectiveness of Assistive Technology for Executive Function Support for People With Acquired Brain Injury: Protocol for Single-Case Experimental Designs. [PDF]

JMIR Res Protoc, 2023
Bould E, Tate R, Simpson G, Brusco N, Licciardi L, Callaway L.   +5 more
europepmc   +1 more source